These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38061261)

  • 21. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease.
    Salminen A; Ojala J; Kaarniranta K; Hiltunen M; Soininen H
    Prog Neurobiol; 2011 Jan; 93(1):99-110. PubMed ID: 21056617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease.
    García-Escudero V; Ruiz-Gabarre D; Gargini R; Pérez M; García E; Cuadros R; Hernández IH; Cabrera JR; García-Escudero R; Lucas JJ; Hernández F; Ávila J
    Acta Neuropathol; 2021 Jul; 142(1):159-177. PubMed ID: 33934221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. γ-Aminobutyric acid type A (GABAA) receptor activation modulates tau phosphorylation.
    Nykänen NP; Kysenius K; Sakha P; Tammela P; Huttunen HJ
    J Biol Chem; 2012 Feb; 287(9):6743-52. PubMed ID: 22235112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pin1: a new outlook in Alzheimer's disease.
    Lonati E; Masserini M; Bulbarelli A
    Curr Alzheimer Res; 2011 Sep; 8(6):615-22. PubMed ID: 21605045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolyl isomerases in gene transcription.
    Hanes SD
    Biochim Biophys Acta; 2015 Oct; 1850(10):2017-34. PubMed ID: 25450176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.
    Brunden KR; Ballatore C; Lee VM; Smith AB; Trojanowski JQ
    Biochem Soc Trans; 2012 Aug; 40(4):661-6. PubMed ID: 22817712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tau Protein Interaction Partners and Their Roles in Alzheimer's Disease and Other Tauopathies.
    Sinsky J; Pichlerova K; Hanes J
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of a 22 kDa Peptidyl Prolyl
    Kang DS; Moon SY; Cho HJ; Lee JM; Kong IS
    J Microbiol Biotechnol; 2017 Mar; 27(3):644-647. PubMed ID: 27840395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parvulin 17 promotes microtubule assembly by its peptidyl-prolyl cis/trans isomerase activity.
    Thiele A; Krentzlin K; Erdmann F; Rauh D; Hause G; Zerweck J; Kilka S; Pösel S; Fischer G; Schutkowski M; Weiwad M
    J Mol Biol; 2011 Aug; 411(4):896-909. PubMed ID: 21756916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies.
    Bakota L; Ussif A; Jeserich G; Brandt R
    Mol Cell Neurosci; 2017 Oct; 84():132-141. PubMed ID: 28318914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roles of Prolyl Isomerases in RNA-Mediated Gene Expression.
    Thapar R
    Biomolecules; 2015 May; 5(2):974-99. PubMed ID: 25992900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Degradation or aggregation: the ramifications of post-translational modifications on tau.
    Park S; Lee JH; Jeon JH; Lee MJ
    BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolyl isomerase, Pin1: new findings of post-translational modifications and physiological substrates in cancer, asthma and Alzheimer's disease.
    Takahashi K; Uchida C; Shin RW; Shimazaki K; Uchida T
    Cell Mol Life Sci; 2008 Feb; 65(3):359-75. PubMed ID: 17965833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies.
    Ramakrishnan P; Dickson DW; Davies P
    Neurobiol Dis; 2003 Nov; 14(2):251-64. PubMed ID: 14572447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolyl isomerases in a minimal cell. Catalysis of protein folding by trigger factor from Mycoplasma genitalium.
    Bang H; Pecht A; Raddatz G; Scior T; Solbach W; Brune K; Pahl A
    Eur J Biochem; 2000 Jun; 267(11):3270-80. PubMed ID: 10824113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40.
    Pirkl F; Buchner J
    J Mol Biol; 2001 May; 308(4):795-806. PubMed ID: 11350175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-translational modifications of tau protein: implications for Alzheimer's disease.
    Martin L; Latypova X; Terro F
    Neurochem Int; 2011 Mar; 58(4):458-71. PubMed ID: 21215781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
    Jangampalli Adi P; Reddy PH
    Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping the stereospecificity of peptidyl prolyl cis/trans isomerases.
    Schiene C; Reimer U; Schutkowski M; Fischer G
    FEBS Lett; 1998 Aug; 432(3):202-6. PubMed ID: 9720925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dementia Therapy Targeting Tau.
    Buee L
    Adv Exp Med Biol; 2019; 1184():407-416. PubMed ID: 32096053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.